Kinexus releases new antibody microarray kit

New protein microarray kit is designed to aid researchers in lead discovery

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced today the release of its first Kinex^TM antibody microarray kit with its latest generation KAM-850 chip. The new antibody microarray is capable of tracking the levels and functional states of hundreds of diverse proteins in human and animal cell and tissue specimens and features more than 330 phosphosite- and 540 pan-specific antibody probes. This provides researchers with a reliable proteomics tool to study changes in cell signaling proteins that occur in response to a range of treatments, drugs, toxins, pathological and other experimental conditions. The KAM-850 chip now provides for the broadest coverage of protein kinase and protein phosphatases targets and their regulatory phosphorylation sites in the market place today with the lowest costs, about US 20¢ per antibody measurement. The purchase costs of commercial antibodies range from 200 to 300 US$ each, so the Kinex™ antibody microarray format offers incredible economy to enable researchers to better identify novel biomarkers for disease diagnostics purposes and for the discovery of new research leads.

"By offering the most affordable and highest quality antibody microarrays, we enable scientists to conduct proteome-wide screening in their own laboratories to further advance signal transduction research that will ultimately help improve patient care", said Dr. Steven Pelech, President and founder of Kinexus and a professor in the Division of Neurology at the University of British Columbia. "We have already used our Kinex^TM antibody microarray to successfully identify panels of candidate biomarkers for Alzheimer's disease and ALS that we are hoping to develop as diagnostic targets."

The Kinex^TM Antibody Microarray Kit is the latest addition to a unique suite of integrated proteomics services and products offered by Kinexus. Discoveries made using the Kinex^TM microarray kit can be quickly validated by Kinexus with its custom Kinetworks^TM immunoblotting services and compared with the results from hundreds of thousands of measurements of protein expression and phosphorylation from thousands of other model systems with the company's open-access KiNET^TM databases and SigNET knowledgebases. To follow-up with detailed characterization of biomarker leads in large specimen sets, Kinexus offers custom reverse lysate microarrays services.

Kinexus currently has agreements with over 1700 research laboratories in companies, universities, government institutions and hospitals in over 35 different countries. To learn more about the Kinex^TM Antibody Microarray Kit or any of the proteomics services available, please visit www.kinexus.ca. Kinexus Bioinformatics Corporation is a private, biotechnology company engaged in the research and development of innovative methods to map, track and manipulate cellular communication networks. The application of this knowledge positions Kinexus and its clients in drug development, rational drug design, disease diagnosis and personalized therapies to improve human health.

SOURCE Kinexus Bioinformatics Corporation